PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.


George Plitas, MD - The Era of Immuno-Oncology in TNBC: Navigating Evidence in Early-Stage and Advanced Disease, Practicalities of Integration, and Implications for Breast Surgeons

Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy has become a new pillar in the treatment arsenal for advanced triple-negative breast cancer (TNBC), and accumulating evidence is supporting its expansion into earlier disease stages as well. To make the most of this therapeutic approach as a component of multimodal management of patients, especially in curative intent settings, it is increasingly important for breast surgeons, medical oncologists, radiation oncologists, pathologists, and other healthcare professionals to collaborate and coordinate the care of patients with TNBC. This educational on-demand activity based on a recent live web broadcast provides up-to-date information and multidisciplinary perspectives on the current and emerging roles of immune checkpoint inhibitors and combinations throughout the disease continuum of TNBC, as well as practical guidance for optimal integration of these therapies into clinical practice, focusing on the most important implications for breast surgeons. Upon completion of this activity, participants will be able to: Discuss the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Assess the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Incorporate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.


 2020-11-02  1h25m